Advertisement



Drug Recalls

Last updated

Every drug recall in FDA enforcement reports from the last three years, plus older recalls that are still open. Filter by severity, status or medicine, and check the lot numbers on your package.

0 Class I (most serious) drug recalls reported in the last 30 days.

311 recalls

  • Class II Ongoing

    Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 4…

    Reason: Presence of Particulate Matter: Due to production issues

    Radnostix · Sodium Iodide I-131

    Lots, distribution and details
    Product
    Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 49353,49457, 49477. (c) 3 ml V-vial, NDC 69208-003-35; Order 49454,49406. Rx Only, Manufactured by: International Isotopes Inc., Idaho Falls, ID.
    Lots / codes
    Batch I012626R-01, Exp 02/09/2026
    Distribution
    Nationwide in the USA and Puerto Rico
    Quantity
    16 units
    Recall started
    January 26, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0389-2026
  • Class II Ongoing

    BioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 – Samrudhhi, Opp. Sakar-III, Navrangpura, Ahmedabad, Gujarat, India – 380014, Email:info@omnilens.in, Manufac…

    Reason: Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

    Wizcure Pharmaa Private Limited

    Lots, distribution and details
    Product
    BioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 – Samrudhhi, Opp. Sakar-III, Navrangpura, Ahmedabad, Gujarat, India – 380014, Email:info@omnilens.in, Manufactured for & disibruted by: HUB Pharmaceuticals, LLC, 8767 E Via de Ventura #175, Scottsdale, AZ, 85258, NDC 17238-900-11.
    Lots / codes
    All lots
    Distribution
    Distributed Nationwide in the USA
    Quantity
    184,320 containers
    Recall started
    December 31, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0352-2026
  • Class II Ongoing

    Bio Glo Fluorescein Sodium Ophthalmic Strips USP, 300 diagnostic strips, Manufactured Omni Lens Pvt Ltd 5 – Samruddhi, Opp. Sakar – III, Navrangpura, Ahmedabad – 380014, India, Email:info@omnilens.in, Manufactured for &…

    Reason: Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

    Wizcure Pharmaa Private Limited

    Lots, distribution and details
    Product
    Bio Glo Fluorescein Sodium Ophthalmic Strips USP, 300 diagnostic strips, Manufactured Omni Lens Pvt Ltd 5 – Samruddhi, Opp. Sakar – III, Navrangpura, Ahmedabad – 380014, India, Email:info@omnilens.in, Manufactured for & distributed by: HUB Pharmaceuticals, LLC, 8767 E Via de Ventura #175, Scottsdale, AZ, 85258, NDC 17238-900-30.
    Lots / codes
    All lots
    Distribution
    Distributed Nationwide in the USA
    Quantity
    50,400 Boxes
    Recall started
    December 31, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0351-2026
  • Class II Ongoing

    CHNaO Fluorescein Sodium Ophthalmic Strips, USP 1mg, packaged as a) 100-count box, NDC 83851-100-10; b) 300-count box, NDC 83851-100-30. Manufactured by Wizcure Pharmaa PVT. LTD, H-681, Phase 3, RIICO Industrial Area, Bh…

    Reason: Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

    Wizcure Pharmaa Private Limited · Fluorescein Sodium

    Lots, distribution and details
    Product
    CHNaO Fluorescein Sodium Ophthalmic Strips, USP 1mg, packaged as a) 100-count box, NDC 83851-100-10; b) 300-count box, NDC 83851-100-30. Manufactured by Wizcure Pharmaa PVT. LTD, H-681, Phase 3, RIICO Industrial Area, Bhiwadi- 301019 INDIA, Vistamerica USA, 20 Perkins Dr. Prescott, AZ 86301, Vistamerica USA, Made in India,
    Lots / codes
    All lots
    Distribution
    Distributed Nationwide in the USA
    Quantity
    10,080 boxes
    Recall started
    December 31, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0350-2026
  • Class II Ongoing

    vancomycin HCl, 2 grams, 2 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-019-59.

    Reason: Lack of Assurance of Sterility

    Fresenius Kabi Compounding, LLC · Vancomycin Hydrochloride

    Lots, distribution and details
    Lots / codes
    Lot # C274-000047611, Exp Date: 10-Feb-26; Lot # C274-000049633, Exp Date: 12-May-26.
    Distribution
    US Nationwide.
    Quantity
    N/A
    Recall started
    February 5, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0337-2026
  • Class II Ongoing

    vancomycin HCl, 1.5 grams, 1.5 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-016-59

    Reason: Lack of Assurance of Sterility

    Fresenius Kabi Compounding, LLC · Vancomycin Hydrochloride

    Lots, distribution and details
    Lots / codes
    Lot # C274-000049628, Exp Date: 3-May-26.
    Distribution
    US Nationwide.
    Quantity
    1578 bags
    Recall started
    February 5, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0336-2026
  • Class II Ongoing

    thiamine HCl, 500 mg, 500 mg added to 100 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-079-56.

    Reason: Lack of Assurance of Sterility

    Fresenius Kabi Compounding, LLC · Thiamine Hydrochloride

    Lots, distribution and details
    Lots / codes
    Lot # C274-000047651, Exp Date: 7-Feb-26; Lot # C274-000048671, Exp Date: 30-Mar-26; Lot # C274-000048828, Exp Date: 7-Apr-26; Lot # C274-000049121, Exp Date: 19-Apr-26; Lot # C274-000049127, Exp Date: 21-Apr-26; Lot # C274-000049252, Exp Date: 26-Apr-26; Lot # C274-000049260, Exp Date: 28-Apr-26; Lot # C274-000049401, Exp Date: 3-May-26; Lot # C274-000049413, Exp Date: 5-May-26; Lot # C274-000049571, Exp Date: 10-May-26; Lot # C274-000049581, Exp Date: 12-May-26; Lot # C274-000049584, Exp Date: 13-May-26; Lot # C274-000049717, Exp Date: 17-May-26; Lot # C274-000049727, Exp Date: 18-May-26.
    Distribution
    US Nationwide.
    Quantity
    10,548 bags
    Recall started
    February 5, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0335-2026
  • Class II Ongoing

    ketamine HCl, 1,000 mg, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-050-56

    Reason: Lack of Assurance of Sterility

    Fresenius Kabi Compounding, LLC · Ketamine Hydrochloride

    Lots, distribution and details
    Lots / codes
    Lot # C274-000047883, Exp Date: 17-Feb-26; Lot # C274-000048515, Exp Date: 22-Mar-26; Lot # C274-000048679, Exp Date: 31-Mar-26; Lot # C274-000049119, Exp Date: 19-Apr-26; Lot # C274-000049282, Exp Date: 27-Apr-26
    Distribution
    US Nationwide.
    Quantity
    1410 bags
    Recall started
    February 5, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0334-2026
  • Class II Ongoing

    acyclovir sodium, 200 mg, 200mg added to 100 mL, 0.9% Sodium Chloride Injection, USP, For Intravenous Use, Single-Use Bag, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-035-56

    Reason: Lack of Assurance of Sterility

    Fresenius Kabi Compounding, LLC · Acyclovir Sodium

    Lots, distribution and details
    Lots / codes
    Lot # C274-000049124, Exp Date: 28-Feb-26.
    Distribution
    US Nationwide.
    Quantity
    1057 bags
    Recall started
    February 5, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0333-2026
  • Class II Ongoing

    Diclofenac Sodium, Topical Gel, 3%, 100 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1363-7

    Reason: Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

    SUN PHARMACEUTICAL INDUSTRIES INC · Diclofenac Sodium

    Lots, distribution and details
    Lots / codes
    Lot # AD92721, Exp Date: 3/31/2027.
    Distribution
    US Nationwide.
    Quantity
    N/A
    Recall started
    January 27, 2026 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0342-2026
  • Class III Ongoing

    Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39

    Reason: Failed PH Specifications

    Cipla USA, Inc. · Diclofenac Sodium

    Lots, distribution and details
    Product
    Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39
    Lots / codes
    Batch XHBG; Exp. 08/31/2027
    Distribution
    Nationwide in the USA
    Quantity
    92,376 tubes
    Recall started
    December 22, 2025 (Voluntary: Firm initiated)
    Severity
    Not likely to cause health problems — for example a labelling or packaging fault.
    FDA recall number
    D-0291-2026
  • Class II Ongoing

    Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured by: LLOYD, Inc., Shenandoah, IA, 51601 USA, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC: 47781-662-10.

    Reason: Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

    Alvogen, Inc · Levothyroxine Sodium

    Lots, distribution and details
    Lots / codes
    Lot # MHA21825, Exp Date: December 31, 2027
    Distribution
    US Nationwide.
    Quantity
    —
    Recall started
    December 31, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0259-2026
  • Class II Ongoing

    0.9% SODIUM CHLORIDE Injection, USP, 100 mL, Rx only, ICU Medical, Inc., Lake Forest, Illinois, 60045, USA, NDC 0990-7984-37

    Reason: Lack of Assurance of Sterility: Potential for flexible container leaks.

    Otsuka ICU Medical LLC · Sodium Acetate Anhydrous

    Lots, distribution and details
    Lots / codes
    Lot # 1029921, Exp Date: 28 February 2027
    Distribution
    Distributed Nationwide in the USA.
    Quantity
    509,360 100 mL bags
    Recall started
    October 27, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0143-2026
  • Class II Ongoing

    R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuV…

    Reason: Presence of Particulate Matter

    QuVa Pharma, Inc.

    Lots, distribution and details
    Product
    R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50
    Lots / codes
    Lot, expiry: 10149179 , exp 10/15/2025 ; 10149503 , exp 10/13/2025 ; 10149504 , exp 10/13/2025 ; 10149657 , exp 10/16/2025 ; 10149658 , exp 10/16/2025 ; 10149659 , exp 10/15/2025 ; 10150137 , exp 10/23/2025 ; 10150138 , exp 10/23/2025 ; 10150139 , exp 10/23/2025 ; 10150140 , exp 10/23/2025 ; 10149729 , exp 10/16/2025 ; 10149730 , exp 10/16/2025 ; 10149732 , exp 10/16/2025 ; 10149733 , exp 10/16/2025 ; 10149737 , exp 10/16/2025 ; 10149738 , exp 10/16/2025 ; 10149790 , exp 10/17/2025 ; 10149787 , exp 10/16/2025 ; 10149788 , exp 10/16/2025 ; 10149791 , exp 10/17/2025 ; 10149792 , exp 10/16/2025 ; 10149800 , exp 10/16/2025 ; 10149841 , exp 10/19/2025 ; 10149833 , exp 10/19/2025 ; 10149840 , exp 10/19/2025 ; 10149842 , exp 10/20/2025 ; 10149838 , exp 10/19/2025 ; 10149839 , exp 10/19/2025 ; 10149843 , exp 10/20/2025 ; 10149968 , exp 10/20/2025 ; 10149969 , exp 10/21/2025 ; 10150007 , exp 10/22/2025 ; 10150134 , exp 10/23/2025 ; 10150253 , exp 10/26/2025 ; 10150254 , exp 10/26/2025 ; 10150135 , exp 10/23/2025 ; 10150302 , exp 10/27/2025 ; 10150303 , exp 10/28/2025 ; 10150182 , exp 10/31/2025 ; 10150183 , exp 10/23/2025 ; 10150185 , exp 10/24/2025 ; 10150184 , exp 10/23/2025 ; 10150186 , exp 10/23/2025 ; 10150187 , exp 10/23/2025 ; 10150204 , exp 10/27/2025 ; 10150357 , exp 10/29/2025 ; 10150358 , exp 10/29/2025 ; 10150361 , exp 10/29/2025 ; 10150362 , exp 10/29/2025 ; 10150525 , exp 10/30/2025 ; 10150526 , exp 10/30/2025 ; 10150527 , exp 10/30/2025 ; 10150528 , exp 10/30/2025 ; 10150532 , exp 10/30/2025 ; 10150533 , exp 10/30/2025 ; 10150534 , exp 10/30/2025 ; 10150535 , exp 10/30/2025 ; 10150537 , exp 10/30/2025 ; 10150538 , exp 10/30/2025 ; 10150550 , exp 10/31/2025 ; 10150551 , exp 10/31/2025 ; 10150596 , exp 11/3/2025 ; 10150597 , exp 11/3/2025 ; 10150598 , exp 11/3/2025 ; 10150599 , exp 11/3/2025 ; 10150616 , exp 11/3/2025 ; 10150617 , exp 11/3/2025 ; 10150619 , exp 11/3/2025 ; 10150620 , exp 11/3/2025 ; 10150631 , exp 11/3/2025 ; 10150632 , exp 11/3/2025 ; 10150633 , exp 11/3/2025 ; 10150634 , exp 11/3/2025 ; 10150613 , exp 11/3/2025 ; 10150614 , exp 11/3/2025 ; 10150677 , exp 11/3/2025 ; 10150720 , exp 11/4/2025 ; 10150650 , exp 11/5/2025 ; 10150778 , exp 11/5/2025 ; 10150779 , exp 11/5/2025 ; 10150883 , exp 11/5/2025 ; 10151024 , exp 11/5/2025 ; 10151025 , exp 11/5/2025 ; 10150884 , exp 11/6/2025 ; 10151061 , exp 11/11/2025 ; 10151069 , exp 11/11/2025 ; 10150944 , exp 11/9/2025 ; 10150945 , exp 11/9/2025 ; 10151121 , exp 11/12/2025 ; 10151129 , exp 11/13/2025 ; 10150948 , exp 11/9/2025 ; 10150949 , exp 11/9/2025 ; 10151184 , exp 11/13/2025 ; 10151195 , exp 11/13/2025 ; 10150961 , exp 11/9/2025 ; 10150980 , exp 11/10/2025 ; 10150981 , exp 11/10/2025 ; 10150984 , exp 11/10/2025 ; 10150985 , exp 11/10/2025 ; 10151013 , exp 11/10/2025 ; 10151051 , exp 11/11/2025 ; 10151052 , exp 11/11/2025 ; 10151055 , exp 11/11/2025 ; 10151056 , exp 11/11/2025 ; 10151070 , exp 11/12/2025 ; 10151071 , exp 11/11/2025 ; 10151014 , exp 11/11/2025 ; 10151072 , exp 11/12/2025 ; 10151074 , exp 11/12/2025 ; 10151075 , exp 11/12/2025 ; 10151078 , exp 11/12/2025 ; 10151079 , exp 11/12/2025 ; 10151111 , exp 11/12/2025 ; 10151112 , exp 11/12/2025 ; 10151115 , exp 11/12/2025 ; 10151116 , exp 11/12/2025 ; 10151130 , exp 11/12/2025 ; 10151131 , exp 11/13/2025 ; 10151132 , exp 11/13/2025 ; 10151134 , exp 11/13/2025 ; 10151135 , exp 11/13/2025 ; 10151138 , exp 11/13/2025 ; 10151139 , exp 11/13/2025 ; 10151173 , exp 11/17/2025 ; 10151174 , exp 11/17/2025 ; 10151177 , exp 11/13/2025 ; 10151178 , exp 11/13/2025 ; 10151196 , exp 11/14/2025 ; 10151197 , exp 11/13/2025 ; 10151199 , exp 11/14/2025 ; 10151200 , exp 11/14/2025 ; 10151203 , exp 11/14/2025 ; 10151204 , exp 11/14/2025 ; 10151418 , exp 11/19/2025 ; 10151419 , exp 11/19/2025 ; 10151423 , exp 11/19/2025 ; 10151424 , exp 11/19/2025 ; 10151442 , exp 11/19/2025 ; 10151443 , exp 11/19/2025 ; 10151447 , exp 11/19/2025 ; 10151448 , exp 11/19/2025 ; 10151462 , exp 11/19/2025 ; 10151463 , exp 11/19/2025 ; 10151464 , exp 11/19/2025 ; 10151466 , exp 11/20/2025 ; 10151468 , exp 11/19/2025 ; 10151467 , exp 11/20/2025 ; 10151470 , exp 11/24/2025 ; 10151471 , exp 11/24/2025 ; 10151475 , exp 11/24/2025 ; 10151476 , exp 11/24/2025 ; 10151505 , exp 11/23/2025 ; 10151506 , exp 11/23/2025 ; 10151509 , exp 11/23/2025 ; 10151510 , exp 11/23/2025 ; 10151523 , exp 11/24/2025 ; 10151524 , exp 11/24/2025 ; 10151525 , exp 11/23/2025 ; 10151527 , exp 11/24/2025 ; 10151528 , exp 11/24/2025 ; 10151531 , exp 11/24/2025 ; 10151532 , exp 11/24/2025 ; 10151546 , exp 11/24/2025 ; 10151547 , exp 11/24/2025 ; 10151550 , exp 11/24/2025 ; 10151551 , exp 11/24/2025 ; 10151563 , exp 11/24/2025 ; 10151564 , exp 11/24/2025 ; 10151567 , exp 11/24/2025 ; 10151568 , exp 11/24/2025 ; 10151580 , exp 11/24/2025 ; 10151581 , exp 11/24/2025 ; 10151582 , exp 11/24/2025 ; 10151584 , exp 11/25/2025 ; 10151585 , exp 11/25/2025 ; 10151588 , exp 11/25/2025 ; 10151589 , exp 11/25/2025 ; 10151600 , exp 11/25/2025 ; 10151601 , exp 11/25/2025 ; 10151604 , exp 11/25/2025 ; 10151605 , exp 11/25/2025 ; 10151705 , exp 11/25/2025 ; 10151706 , exp 11/25/2025 ; 10151707 , exp 11/25/2025 ; 10151711 , exp 11/26/2025 ; 10151727 , exp 11/26/2025 ; 10151728 , exp 11/25/2025 ; 10151729 , exp 11/25/2025 ; 10151770 , exp 11/26/2025 ; 10151771 , exp 11/27/2025 ; 10151788 , exp 11/26/2025 ; 10151789 , exp 11/26/2025 ; 10151969 , exp 12/2/2025 ; 10151979 , exp 12/1/2025 ; 10151980 , exp 12/1/2025 ; 10151970 , exp 12/2/2025 ; 10151981 , exp 12/2/2025 ; 10151982 , exp 12/1/2025 ; 10151971 , exp 12/2/2025 ; 10152008 , exp 12/2/2025 ; 10152009 , exp 12/2/2025 ; 10152010 , exp 12/3/2025 ; 10152060 , exp 12/3/2025 ; 10152061 , exp 12/9/2025 ; 10152011 , exp 12/2/2025 ; 10152121 , exp 12/4/2025 ; 10152122 , exp 12/4/2025 ; 10152012 , exp 12/3/2025 ; 10152064 , exp 12/4/2025 ; 10152123 , exp 12/4/2025 ; 10152124 , exp 12/5/2025 ; 10152178 , exp 12/7/2025 ; 10152062 , exp 12/4/2025 ; 10152175 , exp 12/7/2025 ; 10152179 , exp 12/8/2025 ; 10152180 , exp 12/8/2025 ; 10152063 , exp 12/4/2025 ; 10152176 , exp 12/7/2025 ; 10152177 , exp 12/7/2025 ; 10152323 , exp 12/9/2025 ; 10152339 , exp 12/9/2025 ; 10152374 , exp 12/11/2025 ; 10152340 , exp 12/10/2025 ; 10152341 , exp 12/10/2025 ; 10152375 , exp 12/11/2025 ; 10152371 , exp 12/10/2025 ; 10152372 , exp 12/10/2025 ; 10152376 , exp 12/11/2025 ; 10152373 , exp 12/10/2025 ; 10152393 , exp 12/11/2025 ; 10152428 , exp 12/11/2025 ; 10152394 , exp 12/11/2025 ; 10152395 , exp 12/10/2025 ; 10152429 , exp 12/12/2025 ; 10152774 , exp 12/16/2025 ; 10152775 , exp 12/16/2025 ; 10152834 , exp 12/21/2025 ; 10152835 , exp 12/21/2025 ; 10152861 , exp 12/22/2025 ;
    Distribution
    U.S. Nationwide
    Quantity
    75,885 syringes
    Recall started
    October 10, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0113-2026
  • Class I Ongoing

    Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use, Rx only, IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414-2842 NDC 71139-0012-1

    Reason: Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.

    IntegraDose Compounding Services LLC

    Lots, distribution and details
    Product
    Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use, Rx only, IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414-2842 NDC 71139-0012-1
    Lots / codes
    Lot #: 20250620OXY-1, Expiration date 10/18/2025
    Distribution
    Nationwide in the USA
    Quantity
    853/500 mL bags
    Recall started
    September 16, 2025 (Voluntary: Firm initiated)
    Severity
    Most serious: use could cause serious health problems or death.
    FDA recall number
    D-0015-2026
  • Class II Ongoing

    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehra…

    Reason: Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

    ACCORD HEALTHCARE, INC. · Levothyroxine Sodium

    Lots, distribution and details
    Product
    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.
    Lots / codes
    Lot # D2300045, Exp 12/31/2025.
    Distribution
    Nationwide in the US
    Quantity
    54,432 bottles
    Recall started
    September 16, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0006-2026
  • Class II Ongoing

    Kit for the Preparation of Technetium Tc 99m Mertiatide, Rx Only, Manufactured by: Sun Pharmaceutical Industries, Inc. Billerica, MA 01821, NDC 45567-0655-1

    Reason: Failed Dissolution Specifications-Out of Specification (OOS) observation for sulphate in Sodium Tartrate Dihydrate used for the production of Mertiatide.

    SUN PHARMACEUTICAL INDUSTRIES INC · Betiatide

    Lots, distribution and details
    Lots / codes
    Lot# AD70995; Exp 10/31/2025
    Distribution
    US Nationwide.
    Quantity
    1870 kits
    Recall started
    September 3, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0658-2025
  • Class II Ongoing

    0.9% SODIUM CHLORIDE IRRIGATION USP. ISOTONIC SOLUTION FOR IRRIGATION, 3000mL, Rx only, B. Braun Medical Inc., Bethlehem, PA, 18018, USA, NDC 0264-7388-60.

    Reason: Lack of Assurance of Sterility- Potential for fluid leakage from the port due to port misalignment.

    B BRAUN MEDICAL INC

    Lots, distribution and details
    Lots / codes
    Lot#: : J4C521, J4C516, J4C524, Exp. : 28FEB2027.
    Distribution
    U.S. Nationwide
    Quantity
    16,228 3000 mL bags
    Recall started
    August 26, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0653-2025
  • Class II Ongoing

    4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA, NDC 51754-50…

    Reason: Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

    Exela Pharma Sciences LLC · Sodium Bicarbonate

    Lots, distribution and details
    Product
    4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA, NDC 51754-5012-1 (vial); 51754-5012-4 (carton)
    Lots / codes
    Lot # 10004077, Exp. 02/28/2026
    Distribution
    Nationwide in the USA
    Quantity
    N/A
    Recall started
    July 30, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0620-2025
  • Class I Ongoing

    0.9% Sodium Chloride Injection USP, 1000 mL container, Rx only, B. Braun Medical, Inc., Bethlehem, PA 18018-3524 USA, NDC 0264-7800-09

    Reason: Presence of Particulate Matter.

    B BRAUN MEDICAL INC · Sodium Acetate Anhydrous

    Lots, distribution and details
    Lots / codes
    Lot #: V3K770, Exp 1/31/2026
    Distribution
    U.S.A. Nationwide
    Quantity
    47,148 containers
    Recall started
    August 18, 2025 (Voluntary: Firm initiated)
    Severity
    Most serious: use could cause serious health problems or death.
    FDA recall number
    D-0628-2025
  • Class II Ongoing

    Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bags of 5 prefilled syringes, Rx Only, Dist. by: Sandoz Inc., Princeton, NJ 08540, Outer package – NDC 55154-3543-…

    Reason: Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

    Cardinal Health Inc. · Enoxaparin Sodium

    Lots, distribution and details
    Product
    Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bags of 5 prefilled syringes, Rx Only, Dist. by: Sandoz Inc., Princeton, NJ 08540, Outer package – NDC 55154-3543-5, Inner label – NDC 0781-3238-01
    Lots / codes
    Outer package – NDC 55154-3543-5, Lot SAD08033AA Inner label – NDC 0781-3238-01, Lot SAF13211A
    Distribution
    KS
    Quantity
    10 bags
    Recall started
    August 5, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0597-2025
  • Class III Ongoing

    Sensodyne PRONAMEL (Potassium nitrate 5%, Sodium fluoride 0.25%) Active SHIELD Toothpaste for Sensitive Teeth, Fresh Mint, Net WT 3.4OZ (96.4g) Tube, 6 tubes x 2 inners, per case, Distributed by GSK Consumer Healthcare,…

    Reason: Labeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton

    Haleon US Holdings LLC

    Lots, distribution and details
    Product
    Sensodyne PRONAMEL (Potassium nitrate 5%, Sodium fluoride 0.25%) Active SHIELD Toothpaste for Sensitive Teeth, Fresh Mint, Net WT 3.4OZ (96.4g) Tube, 6 tubes x 2 inners, per case, Distributed by GSK Consumer Healthcare, Warren, NJ 07059. UPC 3 10158 35691 2
    Lots / codes
    Lot # for Case: 5058RB, Exp. date: 08/31/2027 Lot # for Carton and Tube: NJ2A, Exp 08/31/2027
    Distribution
    Nationwide in the USA.
    Quantity
    46,692 tubes
    Recall started
    August 5, 2025 (Voluntary: Firm initiated)
    Severity
    Not likely to cause health problems — for example a labelling or packaging fault.
    FDA recall number
    D-0592-2025
  • Class II Ongoing

    Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14.

    Reason: Lack of Assurance of Sterility.

    PFIZER INC · Sodium Bicarbonate

    Lots, distribution and details
    Product
    Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14.
    Lots / codes
    Lot #: LH2671, Exp. 11/30/2026
    Distribution
    U.S. Nationwide
    Quantity
    15,750 vials
    Recall started
    August 4, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0591-2025
  • Class II Ongoing

    0.9% Sodium Chloride Injection USP, L 8000, 1000mL Excel Container, Rx Only, Sterile, nonpyrogenic, single dose container, B. Braun Medical Inc., Bethlehem, PA 18018, NDC 0264-7800-00.

    Reason: Lack of Assurance of Sterility; potential for fluid leakage at one of the weld sites.

    B BRAUN MEDICAL INC · Sodium Acetate Anhydrous

    Lots, distribution and details
    Lots / codes
    Lot #: J5C919, Exp. 08/31/2027
    Distribution
    Nationwide in the US
    Quantity
    23,100 containers
    Recall started
    August 4, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0586-2025
  • Class II Ongoing

    Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.

    Reason: Subpotent drug

    Pfizer · Levothyroxine Sodium

    Lots, distribution and details
    Lots / codes
    Lot #: 24C11, Exp 2/28/2026.
    Distribution
    Within U.S
    Quantity
    29, 004 bottles
    Recall started
    July 29, 2025 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0575-2025

Have this medicine at home? Compare the lot number and expiry date on your package with the recall. Do not stop taking a prescribed medicine on your own — stopping suddenly can be riskier than the recalled lot. Your pharmacist can check it and usually swap it for an unaffected one.

What the recall classes mean

  • Class I Most serious: use could cause serious health problems or death.
  • Class II Could cause temporary or medically reversible health problems; serious harm is unlikely.
  • Class III Not likely to cause health problems — for example a labelling or packaging fault.

Source: FDA Enforcement Report, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement